Annual CFF
$5.42 M
+$29.50 M+122.49%
December 31, 2024
Summary
- As of March 9, 2025, ARCT annual cash flow from financing activities is $5.42 million, with the most recent change of +$29.50 million (+122.49%) on December 31, 2024.
- During the last 3 years, ARCT annual CFF has fallen by -$42.60 million (-88.72%).
- ARCT annual CFF is now -98.76% below its all-time high of $436.14 million, reached on December 31, 2020.
Performance
ARCT Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$134.00 K
-$559.00 K-80.66%
December 31, 2024
Summary
- As of March 9, 2025, ARCT quarterly cash flow from financing activities is $134.00 thousand, with the most recent change of -$559.00 thousand (-80.66%) on December 31, 2024.
- Over the past year, ARCT quarterly CFF has dropped by -$2.27 million (-94.42%).
- ARCT quarterly CFF is now -99.93% below its all-time high of $187.22 million, reached on September 30, 2020.
Performance
ARCT Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$5.42 M
+$18.79 M+140.51%
December 31, 2024
Summary
- As of March 9, 2025, ARCT TTM cash flow from financing activities is $5.42 million, with the most recent change of +$18.79 million (+140.51%) on December 31, 2024.
- Over the past year, ARCT TTM CFF has dropped by -$2.36 million (-30.31%).
- ARCT TTM CFF is now -98.88% below its all-time high of $483.04 million, reached on March 31, 2021.
Performance
ARCT TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
ARCT Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +122.5% | -94.4% | -30.3% |
| 3 y3 years | -88.7% | +111.0% | +1464.7% |
| 5 y5 years | -87.1% | +111.0% | +1464.7% |
ARCT Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -88.7% | +122.5% | -99.4% | +100.5% | -88.7% | +117.6% |
| 5 y | 5-year | -98.8% | +122.5% | -99.9% | +100.5% | -98.9% | +117.6% |
| alltime | all time | -98.8% | +122.5% | -99.9% | +100.5% | -98.9% | +117.6% |
Arcturus Therapeutics Holdings Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | $5.42 M(-122.5%) | $134.00 K(-80.7%) | $5.42 M(-140.5%) |
| Sep 2024 | - | $693.00 K(-71.2%) | -$13.37 M(-272.0%) |
| Jun 2024 | - | $2.40 M(+9.8%) | $7.77 M(+42.3%) |
| Mar 2024 | - | $2.19 M(-111.7%) | $5.46 M(-122.7%) |
| Dec 2023 | -$24.09 M(+742.5%) | -$18.66 M(-185.4%) | -$24.09 M(+214.4%) |
| Sep 2023 | - | $21.84 M(>+9900.0%) | -$7.66 M(-75.1%) |
| Jun 2023 | - | $94.00 K(-100.3%) | -$30.72 M(+0.5%) |
| Mar 2023 | - | -$27.36 M(+1126.0%) | -$30.56 M(+968.9%) |
| Dec 2022 | -$2.86 M(-106.0%) | -$2.23 M(+83.0%) | -$2.86 M(+620.2%) |
| Sep 2022 | - | -$1.22 M(-574.7%) | -$397.00 K(-126.2%) |
| Jun 2022 | - | $257.00 K(-23.5%) | $1.51 M(+13.1%) |
| Mar 2022 | - | $336.00 K(+46.1%) | $1.34 M(-97.2%) |
| Dec 2021 | $48.02 M(-89.0%) | $230.00 K(-66.8%) | $48.02 M(-77.2%) |
| Sep 2021 | - | $692.00 K(+743.9%) | $210.99 M(-46.9%) |
| Jun 2021 | - | $82.00 K(-99.8%) | $397.52 M(-17.7%) |
| Mar 2021 | - | $47.01 M(-71.2%) | $483.04 M(+10.8%) |
| Dec 2020 | $436.14 M(+940.7%) | $163.20 M(-12.8%) | $436.14 M(+56.9%) |
| Sep 2020 | - | $187.22 M(+118.7%) | $277.98 M(+148.0%) |
| Jun 2020 | - | $85.60 M(>+9900.0%) | $112.08 M(+166.7%) |
| Mar 2020 | - | $118.00 K(-97.7%) | $42.02 M(+0.3%) |
| Dec 2019 | $41.91 M(+310.7%) | $5.03 M(-76.4%) | $41.91 M(-10.3%) |
| Sep 2019 | - | $21.33 M(+37.2%) | $46.74 M(+84.0%) |
| Jun 2019 | - | $15.55 M(>+9900.0%) | $25.40 M(+156.3%) |
| Mar 2019 | - | $0.00(-100.0%) | $9.91 M(-2.9%) |
| Dec 2018 | $10.20 M | $9.87 M(<-9900.0%) | $10.20 M(+635.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | -$19.00 K(-133.3%) | $1.39 M(-25.4%) |
| Jun 2018 | - | $57.00 K(-80.6%) | $1.86 M(-74.5%) |
| Mar 2018 | - | $294.00 K(-72.2%) | $7.29 M(+4.2%) |
| Dec 2017 | $7.00 M(+267.9%) | $1.06 M(+133.1%) | $7.00 M(+17.9%) |
| Sep 2017 | - | $453.00 K(-91.7%) | $5.94 M(+8.3%) |
| Jun 2017 | - | $5.49 M(>+9900.0%) | $5.48 M(<-9900.0%) |
| Mar 2017 | - | $0.00(-100.0%) | -$6000.00(<-9900.0%) |
| Dec 2016 | - | -$6000.00(<-9900.0%) | $0.00(-100.0%) |
| Sep 2016 | - | $0.00(0.0%) | -$26.01 M(0.0%) |
| Jun 2016 | - | $0.00(-100.0%) | -$26.01 M(+0.1%) |
| Mar 2016 | - | $6000.00(-100.0%) | -$26.00 M(-1466.7%) |
| Dec 2015 | $1.90 M(>+9900.0%) | -$26.01 M(<-9900.0%) | $1.90 M(-93.2%) |
| Sep 2015 | - | $0.00(-100.0%) | $27.92 M(0.0%) |
| Jun 2015 | - | $13.00 K(-100.0%) | $27.92 M(+0.0%) |
| Mar 2015 | - | $27.90 M(>+9900.0%) | $27.90 M(>+9900.0%) |
| Dec 2014 | $0.00(-100.0%) | $0.00(0.0%) | $0.00(-100.0%) |
| Sep 2014 | - | $0.00(0.0%) | $35.36 M(0.0%) |
| Jun 2014 | - | $0.00(0.0%) | $35.36 M(-38.3%) |
| Mar 2014 | - | $0.00(-100.0%) | $57.28 M(-0.2%) |
| Dec 2013 | $57.40 M(+9450.4%) | $35.36 M(>+9900.0%) | $57.40 M(+160.5%) |
| Sep 2013 | - | $0.00(-100.0%) | $22.04 M(0.0%) |
| Jun 2013 | - | $21.92 M(>+9900.0%) | $22.04 M(>+9900.0%) |
| Mar 2013 | - | $115.00 K | $115.00 K |
| Dec 2012 | $601.00 K(-77.1%) | - | - |
| Dec 2011 | $2.62 M | - | - |
FAQ
- What is Arcturus Therapeutics Holdings annual cash flow from financing activities?
- What is the all time high annual CFF for Arcturus Therapeutics Holdings?
- What is Arcturus Therapeutics Holdings annual CFF year-on-year change?
- What is Arcturus Therapeutics Holdings quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Arcturus Therapeutics Holdings?
- What is Arcturus Therapeutics Holdings quarterly CFF year-on-year change?
- What is Arcturus Therapeutics Holdings TTM cash flow from financing activities?
- What is the all time high TTM CFF for Arcturus Therapeutics Holdings?
- What is Arcturus Therapeutics Holdings TTM CFF year-on-year change?
What is Arcturus Therapeutics Holdings annual cash flow from financing activities?
The current annual CFF of ARCT is $5.42 M
What is the all time high annual CFF for Arcturus Therapeutics Holdings?
Arcturus Therapeutics Holdings all-time high annual cash flow from financing activities is $436.14 M
What is Arcturus Therapeutics Holdings annual CFF year-on-year change?
Over the past year, ARCT annual cash flow from financing activities has changed by +$29.50 M (+122.49%)
What is Arcturus Therapeutics Holdings quarterly cash flow from financing activities?
The current quarterly CFF of ARCT is $134.00 K
What is the all time high quarterly CFF for Arcturus Therapeutics Holdings?
Arcturus Therapeutics Holdings all-time high quarterly cash flow from financing activities is $187.22 M
What is Arcturus Therapeutics Holdings quarterly CFF year-on-year change?
Over the past year, ARCT quarterly cash flow from financing activities has changed by -$2.27 M (-94.42%)
What is Arcturus Therapeutics Holdings TTM cash flow from financing activities?
The current TTM CFF of ARCT is $5.42 M
What is the all time high TTM CFF for Arcturus Therapeutics Holdings?
Arcturus Therapeutics Holdings all-time high TTM cash flow from financing activities is $483.04 M
What is Arcturus Therapeutics Holdings TTM CFF year-on-year change?
Over the past year, ARCT TTM cash flow from financing activities has changed by -$2.36 M (-30.31%)